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Abstract
Background: Many studies have examined the association between the CYP1A1 MspI and exon 7 gene
polymorphisms and lung cancer risk in various populations, but their results have been inconsistent.
Methods: To assess this relationship more precisely, a meta-analysis and review were performed. The PubMed,
Embase, Web of Science, and CNKI database was searched for case-control studies published up to June 2010.
Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated.
Results: Ultimately, 64 studies, comprising 18,397 subjects from 49 case-control studies of the MspI genotype and
18,518 patients from 40 case-control studies of the exon 7 genotype, were included. A significantly elevated lung
cancer risk was associated with 2 MspI genotype variants (for type C vs Type A: OR = 1.26, 95% CI = 1.12-1.42; for types
B and C combined vs Type A: OR = 1.20, 95% CI = 1.13-1.28) in overall population. In the stratified analysis, a significant
association was found in Asians, Caucasians, lung SCC, lung AC and Male population, not in mixed population, lung
SCLC and Female population. However, inconsistent results were observed for CYP1A1 exon7 in our meta-analysis, two
variants of the exon 7 polymorphism were associated with a significantly higher risk for lung cancer (for Val/Val vs Ile/Ile:
OR = 1.24, 95% CI = 1.09-1.42; for (Ile/Val +Val/Val) vs Ile/Ile: OR = 1.15, 95% CI = 1.07-1.24) in overall population. In the
stratified analysis, a significant assocation was found in Asians, Caucasians, lung SCC and Female population, not in
mixed population, lung AD, lung SCLC and Male population. Additionally, a significant association was found in smoker
population and not found in non-smoker populations for CYP1A1 MspI and exon7 gene.
Conclusions: This meta-analysis suggests that the MspI and exon 7 polymorphisms of CYP1A1 correlate with
increased lung cancer susceptibility and there is an interaction between two genotypes of CYP1A1 polymorphism
and smoking, but these associations vary in different ethnic populations, histological types of lung caner and
gender of case and control population.
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1. Introduction
Lung cancer remains the most lethal cancer worldwide,
despite improvements in diagnostic and therapeutic tech-
niques [1]. Its incidence has not peaked in many parts of
world, particularly in China, which has become a major
public health challenge all the world [2]. The mechanism
of lung carcinogenesis is not understood. Although
cigarette smoking is the major cause of lung cancer, not
all smokers develop lung cancer [3], which suggests that
other causes such as genetic susceptibility might contri-
bute to the variation in individual lung cancer risk [4,5].
Many environmental carcinogens require metabolic acti-
vation by drug-metabolizing enzymes. In recent years,
several common low-penetrance genes have been impli-
cated as potential lung cancer susceptibility genes.
Cytochrome P450 1A1 (CYP1A1) metabolizes several
suspected procarcinogens, particularly polycyclic aromatic
hydrocarbons (PAHs), into highly reactive intermediates
[6]. These compounds bind to DNA to form adducts,
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any medium, provided the original work is properly cited.which, if unrepaired, can initiate or accelerate carcinogen-
esis. Although PAHs are ubiquitous in the environment,
notable sources of exposure that cause the greatest con-
cern include smoking, air pollution, diet, and certain occu-
pations [7]. Two functionally important nonsynonymous
polymorphisms have been described for the CYP1A1
gene, a base substitution at codon 462 in exon 7, resulting
in substitution of isoleucine with valine (Ile462Val (exon
7)) (National Center for Biotechnology Information single
nucleotide polymorphism(SNP) identifier rs1048943;
adenine (A) to guanine (G) substitution at nucleotide 2455
(2455A.G)) and a point mutation (thymine (T) to cytosine
(C)) at the MspI site in the 3’-untranslated region
(rs4646903;3801T.C) [8]. The MspI restriction site poly-
morphism resulted in three genotypes: a predominant
homozygous m1 allele without the MspI site (genotype A),
the heterozygote (genotype B), and a homozygous rare m2
allele with the MspI site (genotype C). The exon 7 restric-
tion site polymorphism resulted in three genotypes: a pre-
dominant homozygous (Ile/Ile), the heterozygote (Ile/Val),
and the rare homozygous(Val/Val).
An association between CYP1A1 polymorphisms and
lung cancer was first reported by Kawajiri and co-workers
in 1990 among an Asian study population (Febs Lett
1990;263:131-133)[9], after which many studies analyzed
the influence of CYP1A1 polymorphisms on lung cancer
risk; no clear consensus, however, was reached. Moreover,
3 meta-analyses have reported conflicting results. Houl-
ston RS [10] found no statistically significant association
between the MspI polymorphism and lung cancer risk in
2 0 0 0 ,i nam e t a - a n a l y s i sp e r f o r m e db yL eM a r c h a n dL
et al. [11] included only 11 studies, the exon 7 polymorph-
ism did not correlate with lung cancer risk. Shi × [12],
however, noted a greater risk of lung cancer for CYP1A1
MspI and exon 7 polymorphism carriers in a meta-analysis
that included only Chinese population.
A single study might not be powered sufficiently to
detect a small effect of the polymorphisms on lung cancer,
particularly in relatively small sample sizes. Various types
of study populations and study designs might also have
contributed to these disparate findings. To clarify the
effect of the CYP1A1 polymorphism on the risk for lung
cancer, we performed an updated meta-analysis of all eligi-
ble case-control studies to date and conducted the sub-
group analysis by stratification according to the ethnicity
source, histological types of lung caner, gender and smok-
ing status of case and control population.
2. Materials and methods
2.1 Publication search
We searched for studies in the PubMed, Embase, Web of
Science, and CNKI (China National Knowledge Infrastruc-
ture) electronic databases to include in this meta-analysis,
using the terms “CYP1A1,”“ Cytochrome P450 1A1,”
“polymorphism,” and “lung cancer.” An upper date limit
of June, 2010 was applied; no lower date limit was used.
The search was performed without any restrictions on lan-
guage and was focused on studies that had been con-
ducted in humans. We also reviewed the Cochrane
Library for relevant articles. Concurrently, the reference
lists of reviews and retrieved articles were searched manu-
ally. When the same patient population appeared in sev-
eral publications, only the most recent or complete study
was included in this meta-analysis.
2.2 Inclusion criteria
For inclusion, the studies must have met the following
criteria: they (1) evaluated CYP1A1 gene polymorphisms
and lung cancer risk; (2) were case-control studies or
nested-case control study; (3) supplied the number of
individual genotypes for the CYP1A1 MspI and exon 7
polymorphisms in lung cancer cases and controls,
respectively; and (4) demonstrated that the distribution
of genotypes among controls were in Hardy-Weinberg
equilibrium.
2.3 Data extraction
Information was extracted carefully from all eligible
publications independently by 2 authors, based on the
inclusion criteria above. Disagreements were resolved
through a discussion between the 2 authors.
The following data were collected from each study: first
author’s surname, year of publication, ethnicity, total
numbers of cases and controls, and numbers of cases and
controls who harbored the MspI and exon 7 genotypes,
respectively. If data from any category were not reported
in the primary study, the items were designated “not
applicable.” We did not contact the author of the primary
study to request the information. Ethnicities were cate-
gorized as Asian, Caucasian, and mixed. Histological type
of lung cancer was divided to lung squamous carcinoma
(SCC), adenocarcinoma (AC) and small cell lung cancer
(SCLC) in our meta-analysis. The definition of smoking
history is very complicated. The smoking histories
covered different periods if changes in the number of
cigarettes smoked per day or type of tobacco products
occurred. Cigarette types were classified as filtered or
unfiltered commercial products and local traditional
hand-made khii yo and yamuan, both unfiltered. Accord-
ing to the general standards, non-smokers were defined
as subjects who had smoked less than 100 cigarettes in
their lifetime. Although the precise definition of never-
smoking status varied slightly among the studies, the
smoking status was classified as non-smokers (or never
smoker) and smokers (regardless of the extent of smok-
ing) in our meta-analysis. We did not require a minimum
number of patients for a study to be included in our
meta-analysis.
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OR (odds ratios) with 95% CIs were used to determine
the strength of association between the CYP1A1MspI
and exon7 polymorphisms and lung cancer risk. We
evaluated this risk with regard to combinations of var-
iants (i.e., type B and type C for MspI and Ile/Val and
Val/Val for exon 7) versus the wild-type homozygotes
(type A for MspI and Ile/Ile for exon 7).
The pooled ORs for the risk were calculated. Subgroup
analyses were performed by ethnicity. Heterogeneity
assumptions were assessed by chi-square-based Q-test
[13]. A P value greater than 0.10 for the Q-test indicated
a lack of heterogeneity among studies, so that the pooled
OR estimate of each study was calculated by the fixed-
effects model (the Mantel-Haenszel method) [14]. Other-
wise, the random-effects model (the DerSimonian and
Laird method) was used [15]. In addition, subgroup ana-
lysis stratified by ethnicity, gender and histological types
of lung caner was also performed.
One-way sensitivity analyses were performed to deter-
mine the stability of the results–each individual study in
the meta-analysis was omitted to reflect the influence of
the individual dataset on the pooled OR [16].
Potential publication biases were estimated by funnel
plot, in which the standard error of log (OR) of each study
was plotted against its log (OR). An asymmetrical plot
suggests a publication bias. Funnel plot asymmetry was
assessed by Egger’s linear regression test, a linear regres-
sion approach that measures the funnel plot asymmetry
on a natural logarithm scale of the OR. The significance of
the intercept was determined by t-test, as suggested by
Egger (P < 0.05 was considered a statistically significant
publication bias) [17].
All calculations were performed using STATA, version
10.0 (Stata Corporation, College Station, TX).
3. Results
3.1 Study characteristics
Two hundred and fifty-seven potentially relevant cita-
tions were reviewed, and 64 publications met the inclu-
sion criteria and included in our meta-analysis [9,18-80].
Study search process was shown in Figure 1. Table 1
presents the principal characteristics of these studies.
For the MspI genotype, 49 studies of 7658 lung cancer
cases and 11839 controls were ultimately analyzed. Rai-
mondi’s study [58] sorted the data for Caucasians and
Asians; therefore, each group in the study was consid-
ered separately in the pooled subgroup analyses. For the
exon7 polymorphism, 40 studies of 6067 lung cancer
cases and 12451 controls were analyzed.
Of the 64 publications, 50 were published in English
and 14 were written in Chinese. The sample sizes ran-
ged from 104 to 1824. All cases were histologically
confirmed. The controls were primarily healthy popula-
tions and matched for age, ethnicity, and smoking
status.
There were 26 groups of Asians, 11 groups of Cauca-
sians, and 12 mixed populations for MspI; for exon7, there
were 22 groups of Asians, 10 groups of Caucasians, and 8
mixed populations. All polymorphisms in the control sub-
jects were in Hardy-Weinberg equilibrium.
3.2 Meta-analysis results
3.2.1 Association of CYP1A1 MspI variant with lung cancer
risk
Table 2 lists the primary results. Overall, a significantly
elevated risk of lung cancer was associated with 2 variants
of CYP1A1 MspI (for Type C vs Type A: OR = 1.26, 95%
CI = 1.12-1.42, P = 0.003 for heterogeneity; for types B
and C combined vs Type A: OR = 1.20, 95% CI = 1.13-
1.28, P = 0.000 for heterogeneity) (Figure 2).
In the stratified analysis by ethnicity, significantly
increased risks were observed among Asians for both type
C vs Type A (OR = 1.24, 95% CI = 1.12-1.43; P = 0.004 for
heterogeneity), types B and C combined vs Type A (OR =
1.30, 95% CI = 1.17-1.44; P = 0.002 for heterogeneity). In
Caucasians, there was also significant association in Type
C vs Type A (OR = 1.25; 95% CI = 1.09-1.36; P = 0.052 for
heterogeneity), types B and C combined vs Type A (OR =
1.35; 95% CI = 1.18-1.54; P = 0.046 for heterogeneity).
However, in mixed populations, no significant associations
were observed (Table 2).
Fourteen [9,19,22,24,26,29,31,32,40,47,53,58,64,78] out
of 64 studies examined the association of CYP1A1 MspI
genotype and the risk of different histological types of lung
cancer including SCC, AC and SCLC. Among lung SCC
and lung AC, significantly increased risks were observed
for both type C vs Type A, types B and C combined vs
Type A. However, among lung SCLC, no significant asso-
ciations were observed for both type C vs Type A (OR =
0.96; 95% CI = 0.70-1.26; P = 0.864 for heterogeneity) or
types B and C combined vs Type A (OR = 1.06; 95% CI =
0.77-1.45; P = 0.976 for heterogeneity) (Figure 3).
Seven [45,56,61,64,74-76] out of 64 studies included
the association of CYP1A1 MspI genotype and lung
caner risk stratified by gender (Male and Female). For
Male population (3 studies), significantly increased risks
were observed for both type C vs Type A (OR = 1.39;
95% CI = 1.23-1.79; P = 0.210 for heterogeneity), types B
and C combined vs Type A (OR = 1.46; 95% CI = 1.07-
1.98; P = 0.380 for heterogeneity). However, for Female
population (7 studies), no significant associations were
observed for both type C vs Type A (OR = 0.92; 95%
CI = 0.84-1.16; P = 0.003 for heterogeneity) or types B
and C combined vs Type A (OR = 0.85; 95% CI = 0.71-
1.02; P = 0.000 for heterogeneity) (Figure 4).
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dies included the association of CYP1A1 MspI genotype
and lung caner risk stratified by smoking status (non-
smokers or never smokers and smokers). For smokers,
significantly increased risks were observed for both type
C vs Type A (OR = 1. 62; 95% CI = 1.33-1.96; P = 0.000
for heterogeneity), types B and C combined vs Type A
(OR = 1.75; 95% CI = 1.44-2.13; P = 0.003 for heteroge-
neity). However, for non-smokers, no significant associa-
tions were observed for both type C vs Type A (OR =
1.18; 95% CI = 0.96-1.186; P = 0.086 for heterogeneity)
or types B and C combined vs Type A (OR = 1.09; 95%
CI = 0.90-1.33; P = 0.114 for heterogeneity) (Figure 5).
3.2.2 Association of CYP1A1 exon7 variant with lung cancer
risk
For all studies in the meta-analysis, the genotype, an
increased risk for lung cancer was associated with 2 exon7
variants (for Val/Val vs Ile/Ile: OR = 1.24, 95% CI = 1.09-
1.42, P = 0.004 for heterogeneity; for Ile/Val and Val/Val
combined vs Ile/Ile: OR = 1.15, 95% CI = 1.07-1.24, P =
0.000 for heterogeneity) (Figure 6).
In the stratified analysis by ethnicity, the risk was higher
in Asian carriers of Val/Val vs Ile/Ile (OR = 1.22, 95%
CI = 1.16-1.59; P = 0.016 for heterogeneity), Ile/Val and
Val/Val combined vs Ile/Ile (OR = 1.21, 95% CI = 1.09-
1.34; P = 0.000 for heterogeneity). A significant association
Figure 1 The flow diagram of search strategy.
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First author-year Ethnicity(country of origin) Total sample size
(case/control)
Lung cancer cases
of MspI genotype
Controls of
MspI genotype
Lung cancer cases
of exon7 genotype
Controls of exon7 genotype
Type B Type C Type A Type B Type C Type A Ile/Val Val/Val Ile/Ile Ile/Val Val/Val Ile/Ile
Kawajiri K-1990 Asia(Japan) 68/104 28 16 24 42 11 51 NA NA NA NA NA NA
Tefre T-1991 Caucasian(Norway) 221/212 47 2 172 43 2 167 NA NA NA NA NA NA
Hirvonen A-1992 Caucasian(Finnish) 87/121 22 0 65 24 2 95 NA NA NA NA NA NA
Shields PG-1993 Mixed populations 56/48 11 2 43 12 3 33 NA NA NA NA NA NA
Nakachi K-1993 Asia(Japan) 31/127 7 13 11 55 11 61 11 6 14 44 4 79
Alexandrie AK-1994 Caucasian(Sweden) 296/329 44 4 248 52 1 276 16 0 280 23 0 306
Kelsey K.T -1994 Mixed(African Americans) 72/97 11 1 60 21 2 74 NA NA NA NA NA NA
Cantlay AM-1995 Caucasian(Edinburgh) 129/281 NA NA NA NA NA NA 21 2 106 33 3 245
Kihara M-1995 Asia(Japan) 97/258 45 16 36 105 41 112 31 5 59 98 14 143
Xu XP-1996 Caucasian(USA) 207/238 35 2 170 48 2 233 NA NA NA NA NA NA
Garcia-ClosaM-1997 Mixed populations 416/446 75 4 337 73 4 369 NA NA NA NA NA NA
Ishibe N-1997 Mixed(Mexican and African) 171/295 68 12 91 106 35 154 31 7 132 70 20 204
Hong YS-1998 Asia(Korean) 85/63 45 6 34 31 3 29 68 1 16 60 1 2
Taioli E-1998 Mixed populations 105/307 30 9 59 101 18 170 8 1 94 18 0 272
Sugimura H-1998 Asia(Japan) 247/185 NA NA NA NA NA NA 94 28 125 84 7 94
Le Marchand L-1998 Mixed populations 341/456 121 35 183 160 44 250 68 6 263 105 13 335
Xue KX-1999 Asia(china) 103/131 NA NA NA NA NA NA 31 18 54 36 11 36
Hu YL-1999 Asia(china) 59/132 22 15 22 76 22 34 33 7 19 102 9 21
London SJ-2000 Asia(China) 214/669 NA NA NA NA NA NA 39 8 167 130 27 512
Dresler CM-2000 Caucasian(USA) 158/149 37* 121 17* 132 NA NA NA NA NA NA
Song N-2001 Asia(China) 217/404 129 28 60 175 56 173 130 9 78 181 13 210
Ratnasinghe D-2001 Caucasian(USA) 282/324 NA NA NA NA NA NA 36 3 243 48 3 273
Quinones L-2001 Caucasians(Chile) 60/174 29 10 16 38 16 86 35 10 15 52 14 54
Chen S-2001 Asia(china) 106/106 NA NA NA NA NA NA 38 10 58 33 3 70
Xue KX-2001 Asia(china) 106/106 NA NA NA NA NA NA 38 10 58 33 3 33
Yin LH-2002 Asia(china) 84/84 34 13 37 38 18 28 NA NA NA NA NA NA
Zhou XW-2002 Asia(china) 92/98 43 15 34 34 13 51 66 11 15 65 6 65
Cai XL-2003 Asia(china) 91/138 23 36 32 46 39 53 NA NA NA NA NA NA
Kiyohara C-2003 Asia(Japan) 158/259 64 17 77 115 28 116 NA NA NA NA NA NA
Taioli E-2003 Mixed populations 109/424 MspI
110/707exon7
20 5 84 75 4 345 16 1 93 70 2 635
Wang J-2003 Asia(china) 162/181 76 22 64 78 38 65 NA NA NA NA NA NA
Dialyna IA-2003 Caucasians (Greek) 122/178 28 5 89 45 3 130 NA NA NA NA NA NA
Dong CT-2004 Asia(china) 82/91 NA NA NA NA NA NA 36 18 28 32 10 32
Gu YF-2004 Asia(china) 180/224 129 * 51 138* 86 NA NA NA NA NA NA
Liang GY-2004 Asia(china) 152/152 82 20 50 71 11 70 NA NA NA NA NA NA
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7Table 1 Distribution of CYP1A1 MspI and exon7 genotypes among lung cancer cases and controls included in this meta-analysis (Continued)
Chen SD-2004 Asia(china) 58/62 15 23 20 20 18 24 NA NA NA NA NA NA
Yang XR-2004 Asia(China) 200/144 NA NA NA NA NA NA 96 11 90 39 7 98
Sobti RC-2004 Asia(India) 100/76 45 6 49 29 5 42 67 29 4 53 15 8
Wenzlaff AS-2005 Caucasian(USA) 128/181 35 0 93 30 4 116 5
# 124 14
# 134
Wrensch MR-2005 Mixed populations 371/944 MspI 363/930exon7 166* 205 472* 472 64
# 302 219
# 711
Ng DP-2005 Asia(Singapore) 126/162 61 22 41 87 19 56 39 13 74 63 7 91
Larsen EJ-2005 Caucasians(Australia) 1050/581 NA NA NA NA NA NA 84 8 958 27 2 552
Raimondi S-2005 Caucasians 165/519 MspI
175/723exon7
43* 122 102* 417 32
# 143 67
# 656
Raimondi S-2005-2 Asians 46/138 MspI
60/212 exon7
28* 18 95* 43 30
# 30 96
# 116
Sreeja L-2005 Asia(Indian) 146/146 53 22 71 45 8 93 NA NA NA NA NA NA
Adonis M-2005 Mixed populations 57/103 31 11 15 33 26 44 NA NA NA NA NA NA
Belogubova-2006 Caucasians (Russian) 141/450 35 2 104 90 3 357 NA NA NA NA NA NA
Li DR-2006 Asia(china) 150/152 NA NA NA NA NA NA 104 14 32 105 8 105
Pisani P-2006 Asia(Thailand) 211/408 87 55 26 155 78 53 79 10 78 129 23 135
Yang MH-2007 Asia(Korea) 314/349 NA NA NA NA NA NA 116 16 182 111 18 220
Tao WH-2007 Asia(china) 47/94 19 4 24 37 14 43 NA NA NA NA NA NA
Cote ML-2007 Mixed populations 354/440 80 5 269 95 6 339 19 0 326 34 6 400
Xia Y-2008 Asia(china) 58/116 36 5 17 58 18 40 NA NA NA NA NA NA
Qi XS-2008 Asia(china) 53/72 29 7 17 38 11 23 NA NA NA NA NA NA
Yoon KA-2008 Asia(Korea) 213/213 NA NA NA NA NA NA 76 10 127 87 10 116
Gallegos-Arreola-2008 Mixed populations 222/248 NA NA NA NA NA NA 91 40 91 104 11 133
Shah PP-2008 Asia(India) 200/200 94* 106 63* 137 67
# 133 44
# 156
Kumar M-2009 Asia(India) 93/253 NA NA NA NA NA NA 17 3 73 40 3 210
Cote ML-2009 Mixed populations 502/523 109 14 373 110 7 402 38 0 464 32 2 489
Honma HN-2009 Mixed populations 200/264 76 11 113 94 9 161 NA NA NA NA NA NA
Klinchid J-2009 Asia(Thailand) 85/82 66* 19 66* 16 47
# 33 42
# 38
Timofeeva MN-2009 Caucasians (German) 619/1264 NA NA NA NA NA NA 248 61 260 545 117 585
Shaffi SM-2009 Asia(India) 109/163 81* 28 85* 78 NA NA NA NA NA NA
Jin Y-2010 Asia(China) 124/154 71* 79 70* 80 NA NA NA NA NA NA
Wright CM-2010 Caucasians (Australian) 1040/784 219 24 797 128 10 646 103 8 929 40 3 741
NA, not applicable; *, the number of the combined of TypeB and TypeC genetypes;
#, the number of the combined Ile/Val and Val/Val genotypes.
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7was also observed in Caucasian carriers of Val/Val vs Ile/
Ile (OR = 1.24; 95% CI = 1.17-1.43; P = 0.090 for heteroge-
neity) and Ile/Val and Val/Val combined vs Ile/Ile (OR =
1.28; 95% CI = 1.12-1.45; P = 0.000 for heterogeneity).
However, no significant associations were observed in
mixed populations for both Val/Val vs Ile/Ile (OR = 0.84;
95% CI = 0.77-1.03; P =0 . 0 9 0f o rh e t e r o g e n e i t y )o rI l e / V a l
and Val/Val combined vs Ile/Ile (OR = 0.92; 95% CI =
0.79-1.06; P = 0.001 for heterogeneity) (Table 2).
Twelve [22,24,29-32,36,40,53,57,58,70] out of 64 studies
examined the association of CYP1A1 exon 7 genotype and
the risk of different histological types of lung cancer
including SCC, AC and SCLC. Among lung SCC, signifi-
cantly increased risks were observed for both Val/Val vs
Ile/Ile (OR = 1.38; 95% CI = 1.12-1.66; P = 0.004 for het-
erogeneity) or Ile/Val and Val/Val combined vs Ile/Ile
(OR = 1.42; 95% CI = 1.18-1.70; P = 0.007 for heterogene-
ity. However, among lung AC and SCLC, no significant
associations were observed for both Val/Val vs Ile/Ile or
Ile/Val and Val/Val combined vs Ile/Ile (Figure 7).
Eight [36,54,56,57,70,74,76,77] out of 64 studies
included the association of CYP1A1 exon 7 genotype and
lung caner risk stratified by gender (Male and Female).
For Female population (3 studies), significantly increased
risks were observed for both Val/Val vs Ile/Ile (OR =
1.29; 95% CI = 1.08-1.51; P = 0.000 for heterogeneity),
Ile/Val and Val/Val combined vs Ile/Ile (OR = 1.24; 95%
CI = 1.05-1.47; P = 0.002 for heterogeneity). However,
for Male population (7 studies), no significant associa-
tions were observed for both Val/Val vs Ile/Ile (OR =
1.18; 95% CI = 0.92-1.35; P = 0.360 for heterogeneity) or
Ile/Val and Val/Val combined vs Ile/Ile (OR = 1.15; 95%
CI = 0.96-1.39; P = 0.298 for heterogeneity) (Figure 8).
Ten [24,31,56,60,70-73] out of 64 studies included the
association of CYP1A1 exon 7 genotype and lung caner
risk stratified by smoking status (non-smokers or never
smokers and smokers). For smokers, significantly
increased risks were observed for both Val/Val vs Ile/Ile
(OR = 1.84; 95% CI = 1.36-2.08; P = 0.003 for heteroge-
neity), Ile/Val and Val/Val combined vs Ile/Ile (OR =
1.62; 95% CI = 1.24-2.11; P = 0.004 for heterogeneity).
However, for non-smokers, no significant associations
were observed for both Val/Val vs Ile/Ile (OR = 1.18;
95% CI = 0.96-1.38; P = 0.080 for heterogeneity) or Ile/
Val and Val/Val combined vs Ile/Ile (OR = 1.07; 95%
CI = 0.88-1.31; P = 0.002 for heterogeneity) (Figure 9).
3.3 Sensitivity analyses
On omission of each individual study, the corresponding
pooled OR was not altered materially (data not shown).
Table 2 Summary ORs for various contrasts of CYP1A1 MspI and exon7 gene polymorphisms in this meta-analysis
Subgroup analysis MspI genotype exon7 genotype
Contrast studies OR(95%) Ph Contrast studies OR(95%) Ph
Total Type C vs Type A
(TypeB+TypeC) vs Type A
49 1.26(1.12-1.42) 0.003
1.20(1.13-1.28) 0.000
Val/Val vs Ile/Ile
(Ile/Val +Val/Val) vs Ile/Ile
40 1.24(1.09-1.42) 0.004
1.15(1.07-1.24) 0.000
Ethnicity
Asian Type C vs Type A
(TypeB+TypeC) vs Type A
26 1.24(1.12-1.43) 0.004
1.30(1.17-1.44) 0.002
Val/Val vs Ile/Ile
(Ile/Val +Val/Val)vs Ile/Ile
22 1.22(1.16-1.59) 0.016
1.21(1.09-1.34) 0.000
Caucasian Type C vs Type A
(TypeB+TypeC) vs Type A
11 1.25(1.09-1.36) 0.053
1.35(1.18-1.54) 0.046
Val/Val vs Ile/Ile
(Ile/Val +Val/Val) vs Ile/Ile
10 1.24(1.17-1.43) 0.090
1.28(1.12-1.45) 0.000
Mixed population Type C vs Type A
(TypeB+TypeC) vs Type A
12 1.05(0.89-1.28) 0.140
1.02(0.92-1.14) 0.330
Val/Val vs Ile/Ile
(Ile/Val +Val/Val) vs Ile/Ile
8 0.84(0.77-1.03) 0.090
0.92(0.79-1.06) 0.001
Histological type
SCC Type C vs Type A
(TypeB+TypeC) vs Type A
13 1.87(1.58-2.14)0.005
1.93(1.62-2.30) 0.000
Val/Val vs Ile/Ile
(Ile/Val +Val/Val) vs Ile/Ile
11 1.38(1.12-1.66) 0.004
1.42(1.18-1.70) 0.007
AC Type C vs Type A
(TypeB+TypeC) vs Type A
12 1.34(1.14-1.56)0.014
1.20(1.01-1.43) 0.000
Val/Val vs Ile/Ile
(Ile/Val +Val/Val) vs Ile/Ile
10 0.90(0.72-1.08) 0.005
0.95(0.79-1.15) 0.001
SCLC Type C vs Type A
(TypeB+TypeC) vs Type A
8 0.96(0.70-1.26)0.864
1.06(0.77-1.45) 0.976
Val/Val vs Ile/Ile
(Ile/Val +Val/Val) vs Ile/Ile
7 0.84(0.68-1.08)0.068
0.78(0.53-1.14) 0.039
Gender
Male Type C vs Type A
(TypeB+TypeC) vs Type A
3 1.39(1.23-1.79) 0.210
1.46(1.07-1.98) 0.380
Val/Val vs Ile/Ile
(Ile/Val +Val/Val) vs Ile/Ile
7 1.18(0.92-1.35) 0.360
1.15(0.96-1.39) 0.298
Female Type C vs Type A
(TypeB+TypeC) vs Type A
7 0.92(0.84-1.16) 0.003
0.85(0.71-1.02) 0.000
Val/Val vs Ile/Ile
(Ile/Val +Val/Val) vs Ile/Ile
3 1.29(1.08-1.51) 0.000
1.24(1.05-1.47) 0.002
Smoking status 13 10
Smokers Type C vs Type A
(TypeB+TypeC) vs Type A
1.62(1.33-1.96) 0.000
1.75(1.44-2.13) 0.003
Val/Val vs Ile/Ile
(Ile/Val +Val/Val) vs Ile/Ile
1.84(1.36-2.08) 0.003
1.62(1.24-2.11) 0.004
Non-smokers Type C vs Type A
(TypeB+TypeC) vs Type A
1.18(0.96-1.48) 0.086
1.09(0.90-1.33) 0.114
Val/Val vs Ile/Ile
(Ile/Val +Val/Val) vs Ile/Ile
1.18(0.96-1.38) 0.080
1.07(0.88-1.31) 0.002
Ph P value of Q-test for heterogeneity test
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Page 7 of 173.4 Publication bias
Begg’s funnel plot and Egger’s test were performed to
identify any publication bias. The funnel plots did not
exhibit any patent asymmetry (Figure 10 and 11). By
Egger’st e s t –used to provide statistical evidence of fun-
nel plot symmetry–there was no evidence of publication
bias (P = 0.558 for publication bias of MspI and P =
0.722 for publication bias of exon 7).
4. Discussion
CYP genes are large families of endoplasmic and cytosolic
enzymes that catalyze the activation and detoxification,
respectively, of reactive electrophilic compounds, includ-
ing many environmental carcinogens (e.g., benzo[a]
pyrene). CYP1A1 is a phase I enzyme that regulates the
metabolic activation of major classes of tobacco procarci-
nogens, such as aromatic amines and PAHs [6]. Thus, it
might affect the metabolism of environmental carcinogens
and alter the susceptibility to lung cancer. This meta-ana-
lysis explored the association between the CYP1A1 MspI
and exon7 gene polymorphisms and lung cancer risk, and
performed the subgroup analysis stratified by ethnicity,
histological types of lung caner, gender and smoking status
of case and control population. Our results indicated a sig-
nificant association between CYP1A1 MspI gene poly-
morphism and lung cancer risk in Asians, Caucasians,
lung SCC, lung AC and Male population, no significant
association was found in mixed population, lung SCLC
Figure 2 Forest plot (random-effects model) of lung cancer risk associated with CYP1A1 MspI for the combined types B and C vs
Type A. Each box represents the OR point estimate, and its area is proportional to the weight of the study. The diamond (and broken line)
represents the overall summary estimate, with CI represented by its width. The unbroken vertical line is set at the null value (OR = 1.0).
Zhan et al. Journal of Experimental & Clinical Cancer Research 2011, 30:99
http://www.jeccr.com/content/30/1/99
Page 8 of 17and Female population. Interestingly, inconsistent results
were observed for CYP1A1 exon7 polymorphism in our
meta-analysis. For the association between CYP1A1 exon7
gene polymorphism and lung cancer risk, a significant
assocation was found in Asians, Caucasians, lung SCC and
Female population, no significant associations were found
in mixed population, lung AD, lung SCLC and Male popu-
lation. Additionally, a significant association was found in
smoker population and not in non-smoker populations for
CYP1A1 MspI and exon7 polymorphisms.
When stratified according to ethnicity, a significantly
increased risks were identified among Asians and Cau-
casians for the 2 MspI genotype variants, however no
significant association was found in mixed population.
For exon 7 polymorphism, the same risk was found in
Asians and Caucasians, not in mixed population. These
findings indicate that polymorphisms of CYP1A1 MspI
and exon 7 polymorphism may be important in specific
ethnicity of lung cancer patients. Population stratifica-
tion is an area of concern, and can lead to spurious evi-
dence for the association between the marker and
disease, suggesting a possible role of ethnic differences
in genetic backgrounds and the environment they lived
in [81]. In fact, the distribution of the less common Val
allele of exon 7 genotype varies extensively between dif-
ferent races, with a prevalence of ~25% among East
Asians,~5% among Caucasians and ~15% among other
population. In addition, in our meta-analysis the
between-study heterogeneity was existed in overall
population, the subgroup of Asian and Caucasian for
MspI and exon 7 genotypes. Therefore, additional stu-
dies are warranted to further validate ethnic difference
in the effect of this functional polymorphism on lung
cancer risk.
Figure 3 Forest plot (random-effects model) of lung cancer risk associated with CYP1A1 MspI for the combined types B and C vs
Type A stratified by histological types of lung cancer.
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Page 9 of 17There are growing biological and epidemiological data
to suggest that different lung cancer pathological subtypes,
particularly the two most common, are distinct etiological
entities that should be analyzed separately [82]. When sub-
group analyses by pathological types were considered,
CYPIAl Mspl and exon7 variant alleles were found to be
associated with a 1.4-1.9 fold increase in the risk of lung
SCC. For lung AC, only CYPIAl Mspl gene polymorphism
was significant, however, for lung SCLC, no significant
association was found for two genotypes. Our findings
were consistent with the Le Marchand L et al study [32]
with largest sample sizes of case and control. Le Marchand
et al. [32] hypothesized that genetic susceptibility to PAHs
predominantly caused lung SCC and nitrosamines caused
lung AC. With introduction of filter-tipped cigarettes,
probably decreased smokers’ exposure to PAHs and
increased their exposure to nitrosamines, decreasing trend
of SCC, relative to the increase in AC indirectly supports
this hypothesis [83]. Different carcinogenic processes may
be involved in the genesis of various tumor types because
of the presence of functionally different CYP1Al Mspl and
exon7 gene polymorphisms. However, the possible mole-
cular mechanisms to explain these histology-specific dif-
ferences in the risk of lung cancer remain unresolved.
Recent epidemiological and biochemical studies have
suggested increased susceptibility to tobacco carcinogens
in women compared to men [84-86]. Moreover, CYP1A1
mRNA expression in the lung has been observed to be
more than two-fold higher in female smokers compared
with male smokers [87]. Another possibly was due to the
effect of circulation estrogens, which have been shown to
induce expression of PAH-metabolizing enzymes, such as
CYP1A1, thereby increasing metabolic activation of car-
cinogens [88]. In premenopausal women, a higher
expression of estrogen can be expected. Estrogen by itself
can be involved in carcinogenesis and additionally, it can
stimulate expression of CYPs in the female. In our meta-
analysis, we found that the effect of CYP1A1 exon7 geno-
type was observed only in Females, however, for CYP1A1
Mspl the effect was only observed among Males. Our
results, along with the previous studies involved above,
suggest the difference roles on the two polymorphisms of
Figure 4 Forest plot (random-effects model) of lung cancer risk associated with CYP1A1 MspI for the combined types B and C vs
Type A stratified by gender of population.
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Page 10 of 17CYP1A1 genotypes in the susceptibility of lung cancer
between Females and Males.
As we know, aside from genetic factor, smoking is the
major risk factor of lung cancer. Most studies out of 64
studies reported information on smoking habits of cases
and controls, however only sixteen eligible publications
provided non-smokers information. Our meta-analysis
results showed that a significantly increased risk was
found to be associated with the CYP1A1 MspI and exon 7
gene polymorphisms and lung cancer risk in smokers,
however, no significant association was found among non-
smokers neither CYP1A1 MspI or exon 7 genotype.
Tobacco smoke contains many of carcinogens and procar-
cinogens, such as benzopyrene and nitrosamine. These
compounds are metabolized by the phase I enzymes
including CYP family enzymes and converted to inactive-
metabolites by the phase II enzymes. Our results should
indicate the interaction between CYP1A1 MspI and exon
7 gene polymorphisms and smoking in the development
of lung carcinoma. However, the association between the
extent of smoke exposure and lung caner risk was not
clear, further studies with larger sample size are needed to
provide insights into the association.
Our data were consistent with the primary results of a
previous meta-analysis [89] that showed the MspI and
Ile-Val polymorphism of CYP1A1 was a risk factor asso-
ciated with increased lung cancer susceptibility and these
associations varied in different ethnic populations. How-
ever, that meta-analysis only conducted the stratified ana-
lysis according to ethnicity, smoking and histological
types and could not analyze the stratified results in-depth.
They could not certify the interaction between smoking
status, the major risk fact of lung cancer, and the two
genotypes of CYP1A1 polymorphism due to the limita-
tion of included studies. We performed more comprehen-
sive stratified analysis by ethnicity, histological types,
smoking status and gender and found the different asso-
ciations in Male and Female population. We concluded
Figure 5 Forest plot (random-effects model) of lung cancer risk associated with CYP1A1 MspI for the combined types B and C vs
Type A stratified by smoking status of population.
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Page 11 of 17Figure 6 Forest plot (random-effects model) of lung cancer risk associated with CYP1A1 exon7 genotype for the combined Ile/Val and
Val/Val vs Ile/Ile.
Figure 7 Forest plot (random-effects model) of lung cancer risk associated with CYP1A1 exon7 genotype for the combined Ile/Val and
Val/Val vs Ile/Ile by histological types of lung cancer.
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Page 12 of 17Figure 8 Forest plot (random-effects model) of lung cancer risk associated with CYP1A1 exon7 genotype for the combined Ile/Val and
Val/Val vs Ile/Ile stratified by gender of population.
Figure 9 Forest plot (random-effects model) of lung cancer risk associated with CYP1A1 exon7 genotype for the combined Ile/Val and
Val/Val vs Ile/Ile stratified by smoking status of population.
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Page 13 of 17that MspI and exon 7 polymorphisms of CYP1A1 corre-
lated with increased lung cancer susceptibility and there
was an interaction between two genotypes of CYP1A1
polymorphism and smoking, but these associations varied
in different ethnic populations, histological types and
gender of case and control population.
Some limitations of this meta-analysis should be
acknowledged. First, heterogeneity can interfere with the
interpretation of the results of a meta-analysis. Although
we minimized this likelihood by performing a careful
search of published studies, using explicit criteria for a
study’s inclusion and performing strict data extraction
and analysis, significant interstudy heterogeneity never-
theless existed in nearly every comparison. The presence
of heterogeneity can result from differences in the selec-
tion of controls, age distribution, and prevalence of life-
style factors. Further, only published studies were
included in this meta-analysis .T h ep r e s e n c eo fp u b l i c a -
tion bias indicates that non-significant or negative
findings might be unpublished. Finally, in the subgroup
analyses, different ethnicities were confused with other
population, which may bring in some heterogeneity. As
studies among the Indians and Africans are currently
limited, further studies including a wider spectrum of
subjects should be carried to investigate the role of these
variants in different populations.
In conclusion, the results of our meta-analysis have
provided the comprehensive and convincing evidence
that CYP1A1 MspI and exon 7 polymorphisms are an
important modifying factor in determining susceptibility
to lung cancer. The effect of two genotypes of CYP1A1
polymorphism is diverse by the subgroup analysis strati-
fied by ethnicity, histological types of lung caner and gen-
der of case and control population. More importantly,
our study confirms that there is an interaction between
two genotypes of CYP1A1 polymorphism and smoking.
For future studies, strict selection of patients, well-
matched controls and larger sample size will be required.
Moreover, gene-gene and gene-environment interactions
should also be considered.
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